The earnings call reflects a positive overall sentiment with notable achievements in clinical trials and substantial financial improvements despite some challenges such as workforce reduction and decreased cash reserves.

Company Guidance -

Q1 2025

During BioAtla's Q1 2025 earnings call, the company provided guidance on several key metrics and developments. BioAtla is progressing well with its Phase 1 dose escalation study of the dual conditionally binding EpCAM and CD3 T cell engager and has not yet reached the maximally tolerated dose. Three patients in the 100 micrograms cohort cleared the dose-limiting toxicity period, and the first three patients in the 300 micrograms cohort have been dosed, with a clinical data readout expected in mid-2025. For the CAB-AXL-ADC Mec-V, the company reported a 2-year landmark survival rate of 59% among mKRAS non-small cell lung cancer patients, which significantly exceeds the less than 20% survival rate observed in previous studies with standard care agents. Mec-V also showed a 1-year landmark survival of 73% in various subtypes of soft tissue sarcoma. Furthermore, the CAB-ROR2-ADC, Oz-V, demonstrated a 100% disease control rate and a 45% overall response rate in metastatic HPV-positive head and neck cancer patients. BioAtla anticipates leveraging its Fast Track Designation for further FDA discussions. Financially, the company reported R&D expenses of $12.4 million, a decrease from $18.9 million in Q1 2024, and a net loss of $15.3 million, down from $23.2 million in the prior year. Cash and cash equivalents stood at $32.4 million as of March 31, 2025, with expectations to fund operations and achieve key clinical readouts in the first half of 2026.

Tumor Reduction in EpCAM and CD3 T Cell Engager Study

Multiple patients in the Phase 1 dose escalation study showed tumor reduction and tolerated the therapy well, with some patients being on therapy for months without progression.

Exceptional Survival with Mec-V

The Mec-V study showed a 59% 2-year survival rate in mKRAS non-small cell lung cancer patients, significantly higher than the less than 20% seen with standard care.

Positive Results in Soft Tissue Sarcoma

Mec-V demonstrated a 73% 1-year landmark survival rate across several subtypes of soft tissue sarcoma.

Compelling Data in HPV Positive Head and Neck Cancer

The CAB-ROR2-ADC, Oz-V, showed a 100% disease control rate and a 45% overall response rate in heavily pretreated metastatic HPV positive head and neck cancer patients.

Strong Financial Management

The company reported a reduced net loss of $15.3 million, down from $23.2 million in the previous year, with significant cost reductions expected to extend runway until 2026.

BioAtla (BCAB) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

BCAB Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 07, 2025	2025 (Q2)	-0.29 / -	-0.44	―	―	―
May 06, 2025	2025 (Q1)	-0.29 / -0.26	-0.48	45.83% (+0.22)	―
Mar 27, 2025	2024 (Q4)	-0.39 / -0.30	-0.56	46.43% (+0.26)	―
Nov 07, 2024	2024 (Q3)	-0.41 / -0.22	-0.7	68.57% (+0.48)	―
Aug 08, 2024	2024 (Q2)	-0.45 / -0.44	-0.75	41.33% (+0.31)	―
May 14, 2024	2024 (Q1)	-0.54 / -0.48	-0.58	17.24% (+0.10)	―
Mar 26, 2024	2023 (Q4)	-0.79 / -0.56	-0.634	11.67% (+0.07)	―
Nov 07, 2023	2023 (Q3)	-0.77 / -0.70	-0.69	-1.45% (-0.01)	―
Aug 01, 2023	2023 (Q2)	-0.64 / -0.75	-0.77	2.60% (+0.02)	―
May 11, 2023	2023 (Q1)	-0.60 / -0.58	-0.65	10.77% (+0.07)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

BCAB Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 06, 2025	$0.48	$0.45	-6.25%
Mar 27, 2025	$0.39	$0.37	-5.13%
Nov 07, 2024	$2.22	$2.10	-5.41%
Aug 08, 2024	$1.47	$1.47	0.00%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.